Karapanagiotou et al. showed that serum resistin levels were higher in lung cancer patients compared with healthy controls [25] while Bonaventura et al. showed that higher serum resistin levels were associated with worse overall survival and that combining resistin levels and neutrophil-lymphocyte ratios could predict NIVO response in advanced NSCLC [26]. This evidence concerns the gene RETN and lung carcinoma.